Agios Pharma (AGIO) AI Stock Analysis

• Market Cap: $2.52B
• Dividend Yield: N/A
• Average Volume (3M): 570.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: 30.57%
• EPS Growth: N/A
• Country: US
• Employees: 486
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.78
• Shares Outstanding: 58,101,517
• 10 Day Avg. Volume: 551,533
• 30 Day Avg. Volume: 570,731
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 51.14
• P/FCF Ratio: -4.77
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $51.83
• Price Target Upside: 19.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 59 Neutral
• Price Target: $45.00 ▲(4.07% Upside)

Agios Pharmaceuticals demonstrates strong growth potential with increasing revenues and a robust pipeline, as highlighted in the earnings call. The stock's undervaluation and positive technical indicators further support its prospects. However, profitability challenges and cash flow inefficiencies are significant risks that weigh on the overall score.

Positive Factors

Strong Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.

Strategic Partnerships

These partnerships enhance Agios's global presence, opening new markets and driving future revenue growth.

Robust Financial Position

A strong cash position provides financial flexibility to invest in R&D and strategic initiatives, supporting long-term growth.

Negative Factors

Profitability Challenges

Sustained profitability issues could hinder reinvestment in growth and affect long-term financial health.

Cash Flow Inefficiencies

Inefficient cash generation may limit the company's ability to fund operations and strategic initiatives.

Revenue Variability

Revenue variability can create uncertainty in financial planning and may impact investor confidence over time.

Agios Pharma Business Overview & Revenue Model

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases, particularly cancer and genetic metabolic disorders. The company specializes in small molecule drugs that target specific metabolic pathways, with a strong emphasis on advancing treatments that address unmet medical needs. Agios's core products include its lead drug, ivosidenib, which is designed for the treatment of acute myeloid leukemia (AML), and other pipeline candidates aimed at various rare diseases.

How the Company Makes Money

Agios Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, particularly ivosidenib, which has been approved by regulatory authorities and is marketed to healthcare providers. The company also earns revenue from collaborations and partnerships with other pharmaceutical companies that may involve co-development or commercialization agreements. These partnerships often provide upfront payments, milestone payments based on the achievement of specific development or sales targets, and royalties on future sales. Additionally, Agios may receive funding from research grants or government initiatives aimed at supporting the development of therapies for rare diseases.

Agios Pharma Financial Statement Overview

Summary

Agios Pharma faces challenges with operational profitability and cash generation, despite maintaining a strong equity base. The income statement shows significant volatility with negative EBIT and EBITDA margins, and cash flow analysis points to negative operating cash flow. However, the balance sheet reveals a strong equity position with a low debt-to-equity ratio.

Income Statement

Agios Pharma's income statement shows significant volatility with negative EBIT and EBITDA margins, indicating operational challenges. Despite recent revenue growth, net profit margins remain negative, reflecting substantial losses. The company's gross profit margin is positive, but overall profitability is impacted by high operational costs.

Balance Sheet

The balance sheet reveals a strong equity position with a low debt-to-equity ratio, indicating financial stability. However, the return on equity is negative due to consistent net losses, which could be concerning if trends don't reverse. The equity ratio is solid, suggesting good asset coverage by equity.

Cash Flow

Cash flow analysis points to negative operating cash flow, indicating potential liquidity issues. Free cash flow remains negative, though there's a positive trend in free cash flow growth recently. The operating cash flow to net income ratio is unfavorable, highlighting the need for improved cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.79M	36.50M	26.82M	14.24M	0.00	203.20M
Gross Profit	37.81M	32.33M	17.32M	12.54M	-18.78M	200.39M
EBITDA	-456.65M	-420.08M	-384.86M	-380.48M	-337.73M	-326.13M
Net Income	-401.26M	673.73M	-352.09M	-231.80M	1.60B	-327.37M
Balance Sheet
Total Assets	1.39B	1.66B	937.12M	1.24B	1.44B	852.95M
Cash, Cash Equivalents and Short-Term Investments	952.86M	893.71M	776.93M	783.12M	1.02B	572.93M
Total Debt	44.52M	56.99M	72.00M	85.66M	97.09M	105.20M
Total Liabilities	101.38M	122.24M	126.10M	137.90M	145.76M	453.45M
Stockholders Equity	1.28B	1.54B	811.02M	1.10B	1.29B	399.50M
Cash Flow
Free Cash Flow	-414.09M	-391.53M	-297.06M	-314.36M	-413.06M	-305.67M
Operating Cash Flow	-409.93M	-389.84M	-296.06M	-309.48M	-407.32M	-290.76M
Investing Cash Flow	237.95M	363.44M	239.57M	243.26M	1.25B	75.75M
Financing Cash Flow	10.96M	14.44M	5.43M	2.35M	-765.77M	261.52M

Agios Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGIO, the sentiment is Positive. The current price of 43.24 is above the 20-day moving average (MA) of 42.10, above the 50-day MA of 39.58, and above the 200-day MA of 34.68, indicating a bullish trend. The MACD of 1.04 indicates Positive momentum. The RSI at 59.40 is Neutral, neither overbought nor oversold. The STOCH value of 57.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGIO.

Agios Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	―	$2.52B	―	-27.57%	―	30.57%	―
NAMS	―	$4.27B	―	-28.43%	―	―	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APGE	―	$3.73B	―	-34.12%	―	―	-79.09%
RXRX	―	$2.46B	―	-86.34%	―	30.14%	-10.08%
DNLI	―	$2.38B	-5.80	-39.69%	―	-100.00%	1.62%
IBRX	―	$2.27B	―	―	―	4227.22%	50.80%

Agios Pharma Corporate Events

Agios Pharmaceuticals Reports Q3 2025 Financial Results

Agios Pharmaceuticals, a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing innovative treatments for rare diseases, particularly in the field of hematology.

Agios Pharmaceuticals Advances Sickle Cell Treatment with Tebapivat Study

Agios Pharmaceuticals is conducting a Phase 2 clinical study titled A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease. The study aims to evaluate the efficacy and safety of tebapivat, a drug intended to improve anemia and hemoglobin response in individuals with Sickle Cell Disease (SCD).

Agios Pharmaceuticals’ AG-236 Study: A Potential Game-Changer in Drug Development

Agios Pharmaceuticals has initiated a Phase 1 clinical trial titled ‘A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants.’ The study aims to evaluate the safety and tolerability of AG-236, a new drug administered via subcutaneous injection, in healthy individuals. This research is significant as it lays the groundwork for further development of AG-236, potentially leading to new therapeutic options.

Agios Pharmaceuticals Advances Mitapivat Study for Sickle Cell Disease and Nephropathy

Agios Pharmaceuticals is spearheading a new clinical study titled ‘A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy (RESIST).’ The study aims to evaluate the effect of mitapivat on the albumin creatinine ratio (ACR) in participants suffering from sickle cell disease (SCD) and nephropathy, a significant step in addressing complications associated with these conditions.

Agios Pharmaceuticals’ Promising Study on Tebapivat for Anemia in LR-MDS

Agios Pharmaceuticals is conducting a study titled ‘A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes.’ The study aims to establish proof of concept for tebapivat in Phase 2a and evaluate its effect on transfusion independence in Phase 2b, targeting patients with lower-risk myelodysplastic syndromes (LR-MDS).

Agios Pharmaceuticals Ensures Continued Access to Mitapivat in New Study

Agios Pharmaceuticals is conducting a study titled ‘A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study.’ The primary objective is to ensure continued access to mitapivat for participants who have completed a previous Agios-sponsored study and lack commercial access to the drug. This study is significant as it addresses ongoing treatment needs for individuals with pyruvate kinase deficiency and hemolytic anemia.

Agios Pharmaceuticals’ AG-181 Study: A Potential Game-Changer in Drug Development

Study Overview: Agios Pharmaceuticals is conducting a Phase 1 clinical trial titled A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AG-181 in Healthy Participants. The study aims to evaluate the safety and tolerability of AG-181, a new drug, in healthy individuals, focusing on single and multiple ascending doses and the effect of food on its pharmacokinetics. This research is significant as it lays the groundwork for understanding AG-181’s potential therapeutic applications.

Agios Pharma’s PYRUKYND Approved by Saudi Authority

Agios Pharmaceuticals addressed a recent securities analyst report detailing adverse event data from the FDA’s reporting system concerning its drug PYRUKYND. The report highlighted four patient cases, but Agios maintains that the information has not changed the drug’s established benefit-risk profile. The company continues to prioritize patient safety through rigorous pharmacovigilance processes. Additionally, on August 4, 2025, the Saudi Food and Drug Authority approved PYRUKYND for treating adult patients with specific types of thalassemia, potentially expanding its market reach.

The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.

Agios Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Agios Pharmaceuticals’ recent earnings call painted a picture of optimism, underscored by robust revenue growth and strategic advancements. The company showcased its strong financial standing and promising clinical trial developments, although it acknowledged challenges such as increased expenses and potential revenue variability. Overall, Agios is on a promising path toward growth, provided it effectively navigates these hurdles.

Agios Pharmaceuticals Reports Q2 2025 Financial Results

Agios Pharmaceuticals, a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing innovative treatments for rare diseases, particularly in the field of hematology.